Niki Procopi
Overview
Explore the profile of Niki Procopi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Procopi N, Montalescot G, Silvain J
Arch Cardiovasc Dis
. 2025 Feb;
118(3):141-143.
PMID: 39986900
No abstract available.
2.
Charleux P, Procopi N, Rahoual G, Proukhnitzky J, Brugier D, Boukhelifa S, et al.
Eur J Prev Cardiol
. 2025 Feb;
PMID: 39950310
Background: Current guidelines fail to adequately identify and prevent cardiovascular prevention in young adults, even when a family history of cardiovascular disease (CVD) is known. Purpose: We aim to assess...
3.
Ritvo P, Charpentier E, Zeitouni M, Rahoual G, Boussouar S, Croisille C, et al.
Eur Heart J Cardiovasc Imaging
. 2025 Jan;
PMID: 39764675
Purpose: Epicardial adipose tissue (EAT) could contribute to the specific atherosclerosis profile observed in premature coronary artery disease (pCAD) characterized by accelerated plaque burden (calcified and non-calcified), high risk plaque...
4.
Silvain J, Materne C, Zeitouni M, Procopi N, Guedeney P, Brugier D, et al.
Eur J Prev Cardiol
. 2024 Nov;
PMID: 39506545
Aims: Low cholesterol efflux capacity and elevated levels of Interleukin-1ß (IL-1ß) are both associated with residual cardiovascular risk in patients with acute myocardial infarction (MI) and may be used as...
5.
Zeitouni M, Dorvillius E, Sulman D, Procopi N, Beaupre F, Devos P, et al.
Am J Cardiovasc Drugs
. 2024 Oct;
25(2):249-258.
PMID: 39432228
Background: This study examines the effects of levosimendan in patients refractory to dobutamine weaning. Methods: This retrospective study included patients with cardiogenic shock refractory to dobutamine weaning failure admitted between...
6.
Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, et al.
N Engl J Med
. 2024 Aug;
391(14):1277-1286.
PMID: 39213187
Background: The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker treatment...
7.
Zeitouni M, Rahoual G, Procopi N, Beaupre F, Michon M, Martinez C, et al.
EuroIntervention
. 2024 Aug;
20(16):1008-1017.
PMID: 39155757
Background: Whether saline-induced hyperaemia captures exercise-induced coronary flow regulation remains unknown. Aims: Through this study, we aimed to describe absolute coronary flow (Q) and microvascular resistance (Rμ) adaptation during exercise...
8.
Sulman D, Beaupre F, Devos P, Procopi N, Kerneis M, Guedeney P, et al.
Arch Cardiovasc Dis
. 2024 Aug;
117(10):569-576.
PMID: 39153876
Background: The ACTION-SHOCK registry offers a decade-long perspective on patients admitted with cardiogenic shock (CS). Aims: To assess trends in the management and outcomes of patients with CS over 10 ...
9.
Manzo-Silberman S, Guedeney P, Cayla G, Beygui F, Range G, Motovska Z, et al.
JACC Cardiovasc Interv
. 2024 Jun;
17(12):1413-1421.
PMID: 38842993
Background: Whether ticagrelor may reduce periprocedural myocardial necrosis after elective percutaneous coronary intervention (PCI) in patients with and without chronic clopidogrel therapy is unclear. Objectives: This study sought to compare...
10.
Zeitouni M, Procopi N, Redheuil A, Collet J
Ann Cardiol Angeiol (Paris)
. 2024 Feb;
73(2):101734.
PMID: 38354637
Since the first description of takotsubo syndrome 30 years ago, only a little is known on the underlying physiopathology leading to peculiar left ventricular function alteration and myocardial damage related...